Ropes & Gray represented Verastem Oncology in a $250 million underwritten offering of common stock and pre-funded warrants, consisting of 30,937,500 shares of its common stock and pre-funded warrants to purchase up to 312,503 shares. The offering priced on October 14 and closed on October 15.
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers.
Ropes & Gray previously advised Verastem on its $90 million public offering of common stock and pre-funded warrants in November 2025.
The Ropes & Gray team was led by capital markets partner Tom Danielski.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.